Expression levels of activated leukocyte cell adhesion molecule (ALCAM/CD166) in primary breast carcinoma and distant breast cancer metastases

Disease Markers

Volumn 28, Issue 2, 2010, Pages 71-78

  Ihnen, M ^a   Kohler N ^a   Kersten, J F ^a   Milde Langosch, K ^a   Beck, K ^a   Holler S ^b   Muller V ^a   Witzel, I ^a   Janicke F ^a   Kilic, E ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Adhesion molecules; ALCAM; breast cancer; distant metastasis; metastasis development

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; PARAFFIN; ALCAM PROTEIN, HUMAN; FETOPROTEIN; LEUKOCYTE ANTIGEN; NERVE CELL ADHESION MOLECULE; TUMOR MARKER;

ADRENAL GLAND; ADULT; AGED; ARTICLE; AUTOPSY; BREAST CARCINOMA; CANCER TISSUE; CORRELATION ANALYSIS; DISTANT METASTASIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCORING SYSTEM; BREAST TUMOR; FEMALE; METABOLISM; METASTASIS; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL ADHESION MOLECULES, NEURONAL; FEMALE; FETAL PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 77954081071     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/2010/812509     Document Type: Article

References (22)

1. W. Degen, L. van Kempen, E.G. Gijzen, J.J. van Groningen, Y. van Kooyk, H.P. Bloemers and G.W. Swart, MEMD, a new cell adhesion molecule in metastasizing human meanoma cell lines is identical to ALCAM (activated leukocyte cell adhesion molecule), Am J Pathol 152 (1998), 805-813.
2. W. Jiang, M. Puntis and M.B. Hallett, Molecular and cellular basis of cancer invasion and metastasis: implications for treatment, Br J Surg 81 (1994), 1576-1590.
3. J. King, S. Ofori-Acquah, T. Stevens, A. Al-Mehdi, O. Fodstad andW.G. Jiang, Activated Leukocyte Cell Adhesion Molecule in breast cancer: prognostic indicator, Breast Cancer Res 6 (2004), 478-487.
4. L. van Kempen, J. Nelissen, W.G.J. Degen, R. Torensma, U.H. Weidle, H.P.J. Bloemers, C.G. Figdor and G.W.M. Swart, Molecular Basis fo the homophilic Activated Leukocyte Cell Adhesion Molecule (ALCAM)-ALCAM interaction, The Journal of Biological Chemistry 276 (2001), 25783-25790.
5. G. Swart, Activated Leukocyte Cell Adhesion Molecule (CD166/ALCAM): Developmental and mechanistic aspects of cell clustering ans cell migration, European Journal of Cell Biology 81 (2002), 313-321.
6. A. Jezierska, P. Wojciech, J. Pietruszkiewicz, W. Olszewski, W. Matysiak andT. Motyl, Activated Leukocyte Cell Adhesion Molecule (ALCAM) is associated with suppression of breast cancer cells invasion, Med Sci Monit 12 (2006), 245-256.
7. S. Bruder, N. Ricalton and R.E. Boynton, Mesenchymal stem cell surface antigen SB-10 corresponds to activated leukocyte cell adhesion molecule and is involved in osteogenic differentiation, J Bone Mineral Res 13 (1998), 655-663.
8. M. Brown, A. Tsodikov, K.R. Bauer, C.A. Parise and V. Caggio, The role of epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptornegative, invasive breast cancer, Cancer 112 (2008), 737-747.
9. O. Ohneda, K. Ohneda and F. Arai, ALCAM (CD166): its role in hematopoietic and endothelial development, Blood 98 (2001), 2134-2142.
10. J. King, S. Ofori-Acquah, T. Stevens and A. Al-Mehdi, Potential role for Activated Leukocyte Cell Adhesion Molecule and Neural Cadherin in metastasis to the lung microcirculation, Chest 125 (2004), 150S-151S.
11. P. Lunter, J. van Kilsdonk, H. van Beek, I.M.H.A. Cornelissen, M. Bergers, P.H.G.M. Willems, G.N.P. van Muijen and G.W.M. Swart, Activated Leukocyte Cell Adhesion Molecule (ALCAM/CD166/MEMD), a novel actor in invasive growth, controls Matrix Metalloproteinase activity, Cancer Res 65 (2005), 8801-8808.
12. G. Kristiansen, C. Pilarsky, C. Wissmann, C. Stephan, L. Weissbach, V. Loy, S. Loening, M. Dietel and A. Rosenthal, ALCAM/CD166 is up-regulated in low-grade prostate cancer and progressivley lost in high-grade lesions, Prostate 54 (2003), 34-43.
13. W. Weichert, T. Knösel, J. Bellach, M. Dietel and G. Kristiansen, ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival, Journal of Clinical Pathology 57 (2004), 1160-1164.
14. A. Verma, N. Shukla, S.V.S. Deo, S.D. Gupta and R. Ralhan, MEMD/ALCAM: A potential marker for tumor invasion and nodal metastasis in esophageal squamous cell carcinoma, Oncology 68 (2005), 462-470.
15. G. Swart, P. Lunter, J.W.J. van Kilsdonk and L.C.L.T. van Kempen, Activated leukocyte cell adhesion molecule (ALCAM/ CD166): signaling at the divide of melanoma cell clustering and cell migration? Cancer Met Rev 24 (2005), 223-236.
16. C. Riley, D. Mahadevan, J.W. Saldanha, W. Qi, L.S. Cooke, Y. Zhu, S.T. Narayan, K. Shakalya, K.D. Croce, I.G. Georgiev, R.B. Nagle, H. Garewal, D.D. von Hoff and D. Mahadevan, Design and activity of a murine and humanized anti-CEACAM6 single-chain variable fragment in the treatment of pancreatic cancer, Cancer Res 69 (2009), 1933-1940.
17. M. Burkhardt, E. Mayordomo, K.J. Winzer, F. Fritzsche, T. Gansukh, S. Pahl, W. Weichert, C. Denkert, H. Guski, M. Dietel and G. Kristiansen, Cytoplasmatic overexpression of ALCAMis prognostic of disease progression in breast cancer., J Clin Pathol 59 (2006), 403-409.
18. M. Ihnen, V. Müller, R.M. Wirtz, C. Schröder, S. Krenkel, I. Witzel, B. Lisboa, F. Jänicke and K. Milde-Langosch, Predictive impact of Activated Leukocyte Cell Adhesion Molecule (ALCAM/CD166) expression in breast cancer, Breast Cancer Res Treatm 112 (2008), 419-427.
19. S. Davies, C. Dent, G. Watkins, J.A. King, K. Mokbel and W.G. Jiang, Expression of the cell to cell adhesion molecule, ALCAM, in breast cancer patients and the potential link with skeletal metastasis, Oncol Rep 19 (2008), 555-561.
20. L. van Kempen, J. van den Oord, G.N.P. van Muijen, U.H. Weidle, H.P.J. Bloemers and G.W.M. Swart, Activated leukocyte adehsion molecule/CD166, a marker of tumor progression in primary malignant melanoma of the skin, Am J Pathol 156 (2000), 769-774.
21. S. Varghese, M. Burness, H. Xu, T. Beresnev, J. Pingpank and H.R. Alexander, Site-specific gene expression profiles and novel molecular prognostic factors in patients with lower gastrointestinal adenocarcinoma diffusely metastatic to liver or peritoneum, Ann Surg Oncol. 14 (2007), 3460-3471.
22. C.W. Elston and I.O. Ellis, Pathological prognostic factors in breast cancer: The value of histological grade in breast cancer: experience from a large study with long-term followup, Histopathology 19 (1991), 403-410.